JPWO2020079165A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020079165A5
JPWO2020079165A5 JP2021521145A JP2021521145A JPWO2020079165A5 JP WO2020079165 A5 JPWO2020079165 A5 JP WO2020079165A5 JP 2021521145 A JP2021521145 A JP 2021521145A JP 2021521145 A JP2021521145 A JP 2021521145A JP WO2020079165 A5 JPWO2020079165 A5 JP WO2020079165A5
Authority
JP
Japan
Prior art keywords
compound
mol
deuterium
group
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512736A (ja
JP2022512736A5 (https=
JP7603199B2 (ja
Publication date
Priority claimed from GBGB1816998.7A external-priority patent/GB201816998D0/en
Priority claimed from GBGB1909695.7A external-priority patent/GB201909695D0/en
Application filed filed Critical
Priority claimed from PCT/EP2019/078250 external-priority patent/WO2020079165A1/en
Publication of JP2022512736A publication Critical patent/JP2022512736A/ja
Publication of JPWO2020079165A5 publication Critical patent/JPWO2020079165A5/ja
Publication of JP2022512736A5 publication Critical patent/JP2022512736A5/ja
Priority to JP2024107578A priority Critical patent/JP2024150488A/ja
Application granted granted Critical
Publication of JP7603199B2 publication Critical patent/JP7603199B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521145A 2018-10-18 2019-10-17 重水素を含有する化合物 Active JP7603199B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024107578A JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1816998.7 2018-10-18
GBGB1816998.7A GB201816998D0 (en) 2018-10-18 2018-10-18 Compounds
GB1909695.7 2019-07-05
GBGB1909695.7A GB201909695D0 (en) 2019-07-05 2019-07-05 Compounds
PCT/EP2019/078250 WO2020079165A1 (en) 2018-10-18 2019-10-17 Compounds containing deuterium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024107578A Division JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Publications (4)

Publication Number Publication Date
JP2022512736A JP2022512736A (ja) 2022-02-07
JPWO2020079165A5 true JPWO2020079165A5 (https=) 2022-10-18
JP2022512736A5 JP2022512736A5 (https=) 2022-10-18
JP7603199B2 JP7603199B2 (ja) 2024-12-20

Family

ID=68290247

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521145A Active JP7603199B2 (ja) 2018-10-18 2019-10-17 重水素を含有する化合物
JP2024107578A Pending JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024107578A Pending JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Country Status (19)

Country Link
US (2) US12152087B2 (https=)
EP (1) EP3866931B1 (https=)
JP (2) JP7603199B2 (https=)
KR (1) KR102848971B1 (https=)
CN (1) CN112930214B (https=)
AU (1) AU2019362389B2 (https=)
BR (1) BR112021007060A2 (https=)
CA (1) CA3116198A1 (https=)
DK (1) DK3866931T3 (https=)
ES (1) ES2942468T3 (https=)
FI (1) FI3866931T3 (https=)
HU (1) HUE061801T2 (https=)
IL (1) IL282231B2 (https=)
MA (1) MA53904A (https=)
MX (1) MX2021004474A (https=)
PL (1) PL3866931T3 (https=)
SG (1) SG11202103726RA (https=)
WO (1) WO2020079165A1 (https=)
ZA (1) ZA202102492B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
EP4347615B1 (en) * 2021-06-01 2025-05-21 Synthon B.V. Process for making melflufen or a salt thereof
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
WO2023281007A1 (en) 2021-07-08 2023-01-12 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations
WO2026057823A1 (en) * 2024-09-13 2026-03-19 Oncopeptides Ab Bis-chloroethylamino derivatives for treating leukemia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CA3024230C (en) * 2011-04-28 2022-10-18 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
WO2014065751A1 (en) * 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
EA202091397A1 (ru) 2013-01-31 2020-09-04 Ауспекс Фармацетикалс, Инк. Бензохинолоновые ингибиторы vmat2
KR20150115807A (ko) * 2013-02-05 2015-10-14 임파 악치엔게젤샤프트 위치-특이적 비대칭 중수소 풍부 카테콜아민 유도체 및 상기 화합물을 포함하는 약제
EA201791466A1 (ru) 2013-12-03 2017-11-30 Оспекс Фармасьютикалз, Инк. Способы получения соединений бензохинолина
CN110229159B (zh) * 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
GB201507903D0 (en) * 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens

Similar Documents

Publication Publication Date Title
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
RU2018106914A (ru) 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция
JP2005523922A5 (https=)
CN113784970A (zh) Erk抑制剂及其应用
JP2019014758A5 (https=)
JP2019517487A5 (https=)
MX2026001061A (es) Inhibidores de la fosfatidilinositol 3-cinasa (pi3k)
JP2019521988A5 (https=)
RU2010126056A (ru) Органические соединения
JP2013510120A5 (https=)
JP2011505347A5 (https=)
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
JP2017530983A5 (https=)
JP2013544276A5 (https=)
RU2020108488A (ru) Бета-гидрокси-гетероциклические амины и их применение для лечения гипергликемии
JP2020111571A5 (https=)
JPWO2020079165A5 (https=)
JP2018172383A5 (ja) 魚介類のベコ病の経口投与用治療剤組成物及びそれを用いた魚介類のベコ病の治療方法
JP2012506908A5 (https=)
RU2011121354A (ru) Синтетические миметики иммунной защиты и их применение
RU2015113959A (ru) Индолины
RU2011100106A (ru) Замещенные бензимидазолы для лечения нейрофиброматоза
UA72945C2 (uk) Сполука (варіанти), фармацевтична композиція, спосіб лікування (варіанти)
CN113439080A (zh) 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
JP2019516726A5 (https=)